Objective: To estimate the clinical effects

lung function and safety of Shenqi Bufei Tang on stable chronic obstructive pulmonary disease(COPD) patient with Lung-Qi deficiency syndrome. Method: A randomized

stratified

single-blind

controlled trial was designed.60 stable COPD patients with Lung-Qi deficiency syndrome in mild or moderate degree were allocated by random number table to therapy group(T

n =30) and control group(C

n =30).The patients received single conventional therapy in the group C and conventional therapy and Shenqi Bufei Tang in the group T for 3 months. Efficacy measures were clinical symptom and lung function and adverse effect in the course of the treatment and after the treatment. Result: The markedly effective rates were 55.17% and the effective rates were 89.66% in treatment group VS. the markedly effective rates of 23.33%

the effective rates of 66.67% in the control group. The clinical symptoms improvement of the therapy group were better than that of the control group ( P <0.05). There was a uptrend to FVC

FEV1

FEV1% pred

FEV1/FVC of the group T after treatment

but there were not significant difference as compared with before treatment. There was a downtrend to FVC

FEV1

FEV1% pred

FEV1/FVC of the group C after treatment

but there were no significant differences as compared with before treatment. There were significant differences in FVC

FEV1

FEV1%pred

FEV1/FVC between the group T and the group C ( P ≤0.05). Conclusion : The management of the conventional therapy associated with Shenqi Bufei Tang could improve the symptoms and stabilize lung function significantly compared with the single conventional therapys on stable COPD patient with lung-Qi deficiency syndrome. Shenqi Bufei Tang may be beneficial and safe in treatment of stable COPD.